){kind=logo}
Loeb & Loeb represented China SXT Pharmaceuticals, Inc., an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, in its $10 million registered direct offering.
The offering consisted of 66,666,666 Class A ordinary shares sold to a single investor at a purchase price of $0.15 per share. The pre-funded warrants were priced at the same amount, less an exercise price of $0.001 per share.
The aggregate gross proceeds from the offering were approximately $10 million. The transaction closed on Jan. 12, 2026.
The Loeb team included Lawrence Venick, managing partner of the firm’s Hong Kong and Beijing offices, Capital Markets associate Rongwei Xie and legal consultant Jason Yu.
For more information, please see the company’s press release.
The offering consisted of 66,666,666 Class A ordinary shares sold to a single investor at a purchase price of $0.15 per share. The pre-funded warrants were priced at the same amount, less an exercise price of $0.001 per share.
The aggregate gross proceeds from the offering were approximately $10 million. The transaction closed on Jan. 12, 2026.
The Loeb team included Lawrence Venick, managing partner of the firm’s Hong Kong and Beijing offices, Capital Markets associate Rongwei Xie and legal consultant Jason Yu.
For more information, please see the company’s press release.
-
Managing Partner, Hong Kong and Beijing Offices -
Associate